Bextra "Likely" To Add Black Box Warning, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer expects that resolution of labeling discussions with FDA will include boxed warning about skin reactions. FDA will have to consider whether to handle issue in context of broader COX-2 class safety review.
You may also be interested in...
Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.
Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.
Bextra Contraindicated In CABG Surgery Patients
Labeling change to add "black box" for serious skin reactions incorporates post-surgery safety data, including results from two coronary artery bypass graft trials that show increased cardiovascular risk with Pfizer's COX-2 inhibitor.